Abstract Library

#4570 Diagnosis of carcinoid heart disease continues to be late delayed

Introduction: Carcinoid heart disease (CHD) is a serious complication of neuroendocrine tumours. It affects patients with carcinoid syndrome and results from fibrotic deposits on the heart valves. It significantly impacts patient prognosis.

Conference:

Presenting Author:

Authors: Sharma J, Shah T, Coldham C, Vickrage S, Rehman Z,

Keywords: carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, symptoms, presentation, echocardiogram, heart valves,

#4459 Sequential alkylating therapy and pembrolizumab induce near-complete response in high tumour mutational burden pancreatic neuroendocrine tumour: A case report

Introduction: Traditional treatment for neuroendocrine tumours (NETs), including surgery, somatostatin therapy, and targeted therapy, often fails in advanced disease. Alkylating therapy can increase tumour mutational burden (TMB), and the recent KEYNOTE-158 study approved pembrolizumab for advanced solid tumours with a high TMB.

Conference:

Presenting Author:

Authors: Paranjpe I, Hornbacker K, Vadde S, Fisher G, Shaheen S,

Keywords: pancreatic neuroendocrine tumour, immunotherapy, pembrolizumab, tumour mutational burden, TMB,

#4096 Co-production of patient information: A model for today’s practice

Introduction: According to the British Medical Association, good quality patient information is fundamental to effective, patient-centred, quality care. It rightly considers patients as partners in their care, “Co-production involves engaging groups of people who use healthcare services, in equal partnership; at the earliest stages of service design, development and evaluation. It acknowledges that people with ‘lived experience’ of a particular condition are often best placed to advise on what support and services will make a positive difference to their lives.” (NHS England) The re-introduction of a liver transplantation programme in the UK for selected patients with a Neuroendocrine Neoplasm offers new opportunities to improve survival and quality of life: good quality information is a key tool for informed consent.

Conference:

Presenting Author:

Authors: Jervis N, Ellis C, Smith S, Shah T, Lewis K,

Keywords: Liver Transplantation, Co-production, Patient Information, Lived Experience Contribution,

#3871 A phase 2, randomized, parallel-group study to evaluate the safety, pharmacokinetics, and dose response of paltusotine treatment in patients with carcinoid syndrome

Introduction: While long-acting somatostatin receptor ligands (SRLs) are mainstay treatments for carcinoid syndrome (CS), symptom relief at labelled doses is inadequate for many patients. Paltusotine is a novel oral, nonpeptide, selective somatostatin receptor type 2 agonist. In patients with acromegaly, paltusotine maintains plasma IGF-1 levels in patients switching from long-acting SRLs. Paltusotine was well tolerated in phase 2 acromegaly studies.

Conference:

Presenting Author:

Authors: Chauhan A, Shaheen S, Usiskin K, Odueyungbo A, Mui C,

Keywords: Paltusotine, Phase 2 trial, Somatostatin receptor agonist, Safety, Pharmacokinetics, Carcinoid syndrome,

#3849 Is patient's BMI representative of their body composition in neuroendocrine tumors?

Introduction: Up to 60% of patients with neuroendocrine tumors (NETs) are malnourished. This negatively impacts survival, length of hospital stay, risk of complications, treatment response, fatigue and quality of life. Malnutrition is typically defined by body mass index (BMI) or weight loss, which provides no information on body composition. Research in other cancers has shown sarcopenia is more significant than BMI. Information is lacking on the influence of anthropometric parameters in NETs.

Conference:

Presenting Author: Bradley E

Authors: Bradley E, Shah T,

Keywords: neuroendocrine, body composition, handgrip strength, mid arm muscle circumference,